天士力(600535.SH):藿香正氣滴丸等產品列入《新型冠狀病毒肺炎診療方案(試行第九版)》
格隆匯3月18日丨天士力(600535.SH)公佈,近日,國家衞生健康委員會辦公廳和國家中醫藥管理局辦公室聯合發佈《新型冠狀病毒肺炎診療方案(試行第九版)》,公司及控股子公司的藿香正氣滴丸被該方案列為醫學觀察期推薦用藥,醒腦靜注射液被列為重型和危重型推薦用藥,安宮牛黃丸被列為危重型推薦用藥。
公司預計此次《新型冠狀病毒肺炎診療方案(試行第九版)》的發佈將對上述產品的市場推廣和銷售產生積極影響,上述產品的銷售情況受疫情防控等因素影響存在較大不確定性,目前相關業務規模佔公司整體業務量比重較小,對公司近期經營業績無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.